MedTrace Logo

Avelox in Complicated Skin and Skin Structure Infections

NCT00997997 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6127

Last updated 2012-11-16

No results posted yet for this study

Summary

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

Conditions

  • Skin Diseases, Bacterial

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Austria
  • Bulgaria
  • Egypt
  • Germany
  • Greece
  • Indonesia
  • Pakistan
  • Philippines
  • Saudi Arabia
  • Slovenia
  • South Korea
  • Taiwan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997997 on ClinicalTrials.gov